RedHill Biopharma Faces Nasdaq Compliance Challenge

The latest update is out from RedHill Biopharma ( (RDHL) ).

On April 17, 2025, RedHill Biopharma announced receiving a notification from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement. The company reported a stockholders’ deficit of $4,683,000 as of December 31, 2024. While this notification does not immediately affect RedHill’s Nasdaq listing or operations, the company has until May 30, 2025, to submit a compliance plan. RedHill is exploring options to regain compliance, though there is no guarantee the plan will be accepted.

Spark’s Take on RDHL Stock

According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.

RedHill Biopharma is currently facing major financial difficulties with negative equity, high debt, and cash flow issues. The technical analysis reflects a bearish outlook with the stock trading below key averages. Valuation concerns due to the lack of earnings and dividends further support a cautious stance.

To see Spark’s full report on RDHL stock, click here.

More about RedHill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. The company promotes Talicia, an FDA-approved drug for Helicobacter pylori infection, and is involved in various late-stage clinical development programs targeting conditions such as COVID-19, Crohn’s disease, and cancer.

YTD Price Performance: -67.66%

Average Trading Volume: 198,672

Technical Sentiment Signal: Buy

Current Market Cap: $2.72M

For a thorough assessment of RDHL stock, go to TipRanks’ Stock Analysis page.